Clinical Trial Update: Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating fixed doses of rhPTH(1-84) (25 and 50 mcg) in adults with hypoparathyroidism; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• rhPTH(1-84) (recombinant human parathyroid hormone 1-84)

Snippet

Sponsor: Shire | Conditions: Hypoparathyroidism | Phase 3 | Status: COMPLETED | Results posted: 2015-03-06